Alterity Therapeutics Limited American Depositary Shares (ATHE)
Stock · NASDAQ · Health Care
$2.39as of 10/16/2026
Price chart
Active signals
ATHE Signal Track Record
How signals performed across all stocks →What ATHE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | +4.2% | 59% | October 2, 2026 |
| Bollinger Band BreakdownActive now | 28 | +2.6% | 57% | October 8, 2026 |
| Bollinger Band Breakout | 21 | -7.6% | 38% | July 6, 2026 |
| 200-Day Moving Average TouchActive now | 7 | +9.4% | 57% | September 11, 2026 |
| Any 20-session window (baseline) | -3.6% | 38% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ATHE
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to tr…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 11
- Website
- alteritytherapeutics.com/
Fundamentals
- 1-day range
- $2.35$2.96
- Market cap
- $82.65M
- P/E (trailing)
- —
- P/E (forward)
- -2.77
- EPS (trailing)
- $-0.11
- Dividend yield
- —
- Beta
- 1.23
- Avg. volume
- 17.9K
Forecasts
4 analyst ratings
Alterity Therapeutics Limited American Depositary Shares Competitors
Chosen by industry and closest market cap.
- ATHEAlterity Therapeutics Limited American Depositary Shares$2.62▼ 3.68%Market cap $82.65MP/E —$0.01$0.785
- LFVNLifevantage Corporation Common Stock (Delaware)$6▲ 0.00%Market cap $83.01MP/E 14.40$3.9$11.71
- TELOTelomir Pharmaceuticals Inc. Common Stock$1.05▲ 0.00%Market cap $80.47MP/E —$0.8884$1.75
- MAIAMAIA Biotechnology Inc. Common Stock$1.1▼ 1.79%Market cap $86.34MP/E —$0.87$3.19
- GOSSGossamer Bio Inc. Common Stock$8.77▼ 1.35%Market cap $87.21MP/E —$8.77$309.6
- GANXGain Therapeutics Inc. Common Stock$1.26▼ 5.26%Market cap $75.92MP/E —$1.3$4.34
- NMADNomad Power Solutions Inc. Common Stock$3.88▼ 5.13%Market cap $75.50MP/E —$3.12$7.7
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ATHE Alterity Therapeutics Limited American Depositary Shares | $82.65M | — | $2.62 | ▼ 3.68% | $0.01$0.785 |
| LFVN Lifevantage Corporation Common Stock (Delaware) | $83.01M | 14.40 | $6 | ▲ 0.00% | $3.9$11.71 |
| TELO Telomir Pharmaceuticals Inc. Common Stock | $80.47M | — | $1.05 | ▲ 0.00% | $0.8884$1.75 |
| MAIA MAIA Biotechnology Inc. Common Stock | $86.34M | — | $1.1 | ▼ 1.79% | $0.87$3.19 |
| GOSS Gossamer Bio Inc. Common Stock | $87.21M | — | $8.77 | ▼ 1.35% | $8.77$309.6 |
| GANX Gain Therapeutics Inc. Common Stock | $75.92M | — | $1.26 | ▼ 5.26% | $1.3$4.34 |
| NMAD Nomad Power Solutions Inc. Common Stock | $75.50M | — | $3.88 | ▼ 5.13% | $3.12$7.7 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Alterity Therapeutics Says ATH434 50 mg Slowed Multiple System Atrophy Decline By About 52% In Post Hoc Phase 2 Analysisbenzinga · 10/5/2026
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga · 10/2/2026
- Alterity Therapeutics CEO speaks with Proactive at the ASX SMIDcaps ConferenceYahoo · 9/23/2026
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga · 9/16/2026
- Lake Street Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $10Benzinga · 9/15/2026
Insider Activity
Insider Actions →- Stamler David Allen · August 31, 2026 · Buy47.6K @ $0.5
- Marks Peter Ashley · August 31, 2026 · Buy47.6K @ $0.5
- Babarczy Julian Michael · June 15, 2026 · Grant2.00M
- Gozlan Lawrence Bernard · June 15, 2026 · Grant1.00M
Institutional Ownership
March 31, 2026
- Total shares held
- 320.8K
- Total value held
- $1.11M
- Institutional holders
- 15
- Unknown139.3K
- Unknown58.5K
- Unknown58.4K
- Unknown32.0K
- Unknown20.1K
- Unknown6.8K
- Unknown2.0K
- Unknown1.9K
- Unknown1.9K
- Unknown68
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Alterity CEO speaks at ASX SMIDcaps Conference
Alterity Therapeutics CEO spoke at the ASX SMIDcaps Conference, sharing insights on the company's progress. The appearance highlights ongoing engagement with investors and industry peers. Shares are currently trading near a key support level at $4.50.
Alterity CEO speaks at ASX SMIDcaps Conference. Alterity Therapeutics CEO spoke at the ASX SMIDcaps Conference, sharing insights on the company's progress. The appearance highlights ongoing engagement with investors and industry peers. Shares are currently trading near a key support level at $4.50.